These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 34311745

  • 21. Lipoprotein Glomerulopathy, First Case Report from Canada.
    Ting JA, McRae SA, Schwartz D, Barbour SJ, Riazy M.
    Int J Nephrol Renovasc Dis; 2022; 15():207-214. PubMed ID: 35761986
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.
    Saito T, Matsunaga A, Oikawa S.
    Am J Kidney Dis; 2006 Feb; 47(2):199-211. PubMed ID: 16431249
    [Abstract] [Full Text] [Related]

  • 24. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy.
    Toyota K, Hashimoto T, Ogino D, Matsunaga A, Ito M, Masakane I, Degawa N, Sato H, Shirai S, Umetsu K, Tamiya G, Saito T, Hayasaka K.
    J Hum Genet; 2013 May; 58(5):254-8. PubMed ID: 23407349
    [Abstract] [Full Text] [Related]

  • 25. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.
    Hu Z, Huang S, Wu Y, Liu Y, Liu X, Su D, Tao Y, Fu P, Zhang X, Peng Z, Zhang S, Yang Y.
    Kidney Int; 2014 Feb; 85(2):416-24. PubMed ID: 24025644
    [Abstract] [Full Text] [Related]

  • 26. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.
    Matsunaga A, Saito T.
    Clin Exp Nephrol; 2014 Apr; 18(2):220-4. PubMed ID: 24570178
    [Abstract] [Full Text] [Related]

  • 27. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy.
    Tokura T, Itano S, Kobayashi S, Kuwabara A, Fujimoto S, Horike H, Satoh M, Komai N, Tomita N, Matsunaga A, Saito T, Sasaki T, Kashihara N.
    J Atheroscler Thromb; 2011 Apr; 18(6):536-41. PubMed ID: 21467726
    [Abstract] [Full Text] [Related]

  • 28. [Clinicopathologic features of lipoprotein glomerulopathy: observation of 6 cases].
    Zou GM, Zhuo L, Tan M, Li WG.
    Zhonghua Yi Xue Za Zhi; 2018 Sep 25; 98(36):2910-2913. PubMed ID: 30293348
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features.
    Saito T, Oikawa S, Sato H, Sato T, Ito S, Sasaki J.
    Kidney Int Suppl; 1999 Jul 25; 71():S37-41. PubMed ID: 10412734
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A Case of Lipoprotein Glomerulopathy with apoE Chicago and apoE (Glu3Lys) Treated with Fenofibrate.
    Kodera H, Mizutani Y, Sugiyama S, Miyata T, Ehara T, Matsunaga A, Saito T.
    Case Rep Nephrol Dial; 2017 Jul 25; 7(2):112-120. PubMed ID: 28966924
    [Abstract] [Full Text] [Related]

  • 34. A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.
    Stratikos E, Chroni A.
    Clin Exp Nephrol; 2014 Apr 25; 18(2):225-9. PubMed ID: 24149834
    [Abstract] [Full Text] [Related]

  • 35. Lipoprotein glomerulopathy with a novel apolipoprotein E variant, APOE Kanto (Asp 151dup).
    Yokochi A, Matsunaga A, Kanemoto K, Tominaga N, Uda S, Saito T.
    CEN Case Rep; 2024 Aug 14. PubMed ID: 39141311
    [Abstract] [Full Text] [Related]

  • 36. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
    Arai T, Yamashita S, Yamane M, Manabe N, Matsuzaki T, Kiriyama K, Kanayama Y, Himeno S, Matsuzawa Y.
    Atherosclerosis; 2003 Aug 14; 169(2):293-9. PubMed ID: 12921981
    [Abstract] [Full Text] [Related]

  • 37. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.
    Ishigaki Y, Oikawa S, Suzuki T, Usui S, Magoori K, Kim DH, Suzuki H, Sasaki J, Sasano H, Okazaki M, Toyota T, Saito T, Yamamoto TT.
    J Biol Chem; 2000 Oct 06; 275(40):31269-73. PubMed ID: 10903326
    [Abstract] [Full Text] [Related]

  • 38. Lipoprotein glomerulopathy: a rare cause of steroid-resistant nephrotic syndrome in a child.
    Vala K, Shah K, Kapadia S, Khandelwal M, Jojera A, Soni S, Prajapati A, Saha A.
    CEN Case Rep; 2024 Oct 06; 13(5):403-407. PubMed ID: 38438730
    [Abstract] [Full Text] [Related]

  • 39. Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice.
    Wu H, Yang J, Liu YQ, Lei S, Yang M, Yang Z, Yang Y, Hu Z.
    J Transl Med; 2021 Mar 04; 19(1):97. PubMed ID: 33663537
    [Abstract] [Full Text] [Related]

  • 40. [Identification of a mutation in exon 4 of apolipoprotein E gene in a family affected with lipoprotein glomerulopathy].
    Han HL, Lin S, Sun LS, Zhang P, Zhai DP.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr 04; 29(2):141-4. PubMed ID: 22487820
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.